Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-18T04:14:25.242Z Has data issue: false hasContentIssue false
  • English
  • Français

Decoding the ‘embryonic’ nature of embryonal rhabdomyosarcoma

Published online by Cambridge University Press:  05 March 2015

R. Lav Open the ORCID record for R. Lav [Opens in a new window] ,
R. Heera  and
L. M. Cherian
R. Lav*
Affiliation:
Department of Oral Pathology and Microbiology, Government Dental College, Gandhinagar, Kottayam, India
R. Heera
Affiliation:
Department of Oral Pathology and Microbiology, Government Dental College, Gandhinagar, Kottayam, India
L. M. Cherian
Affiliation:
Department of Oral Pathology and Microbiology, Government Dental College, Gandhinagar, Kottayam, India
*
*Address for correspondence: R. Lav, Department of Oral Pathology and Microbiology, Government Dental College, Medical College P.O., Gandhinagar, Kottayam 686008, India (Email rupali.lav@gmail.com)
Get access Rights & Permissions [Opens in a new window]

Abstract

Embryonal rhabdomyosarcoma is one of the major defined histologic variants of rhabdomyosarcoma that is mainly reported in children. The histologic appearance of this neoplastic entity recapitulates normal myogenesis. The tumor cells variably exhibit the different cellular phases of myogenesis ranging from undifferentiated mesenchymal cells to elongated myoblasts, multinucleated myotubes and differentiated muscle fibers. The carefully orchestrated embryonic signaling pathways that are involved in myogenesis, conceivably also result in the genesis of rhabdomyosarcoma; albeit as a corollary to an imbalance. We have attempted to review the pathogenesis of embryonal rhabdomyosarcoma in an endeavor to understand better, how closely it is linked to normal myogenesis in terms of its molecular dynamics and histologic presentation.

Keywords

embryonalmyogenesispathogenesisrhabdomyosarcoma
Type
Review
Information
Journal of Developmental Origins of Health and Disease , Volume 6 , Issue 3 , June 2015 , pp. 163 - 168
Check for updates
Copyright
© Cambridge University Press and the International Society for Developmental Origins of Health and Disease 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Ognjanovic, S, Linabery, AM, Charbonneau, B, Ross, JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States (1975–2005). Cancer. 2009; 115, 4218–4226.CrossRefGoogle ScholarPubMed
2. Parham, DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol. 2001; 14, 506–514.CrossRefGoogle ScholarPubMed
3. Belyea, B, Kephart, JG, Blum, J, Kirsch, DG, Linardic, CM. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma. 2012; 2012, 406239.Google Scholar
4. Bentzinger, CF, Wang, YX, Rudnicki, MA. Building muscle: molecular regulation of myogenesis. Cold Spring Harb Perspect Biol. 2012; 4: 1–16. pii: a008342.Google Scholar
5. Kuang, S, Gillespie, MA, Rudnicki, MA. Niche regulation of muscle satellite cell self-renewal and differentiation. Cell Stem Cell. 2008; 2, 22–31.CrossRefGoogle ScholarPubMed
6. Kuroda, K, Tani, S, Tamura, K, et al. Delta-induced Notch signaling mediated by RBP-J inhibits MyoD expression and myogenesis. J Biol Chem. 1999; 274, 7238–7244.CrossRefGoogle ScholarPubMed
7. Buas, MF, Kabak, S, Kadesch, T. The Notch effector Hey1 associates with myogenic target genes to repress myogenesis. J Biol Chem. 2010; 285, 1249–1258.Google Scholar
8. Wilson-Rawls, J, Molkentin, JD, Black, BL, Olson, EN. Activated Notch inhibits myogenic activity of the MADS-box transcription factor myocyte enhancer factor 2C. Mol Cell Biol. 1999; 19, 2853–2862.Google Scholar
9. Ono, Y, Calhabeu, F, Morgan, JE, et al. BMP signalling permits population expansion by preventing premature myogenic differentiation in muscle satellite cells. Cell Death Differ. 2011; 18, 222–234.CrossRefGoogle ScholarPubMed
10. Liu, F, Ventura, F, Doody, J, Massague, J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol. 1995; 15, 3479–3486.Google Scholar
11. McKinsey, TA, Zhang, CL, Olson, EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci. 2002; 27, 40–47.CrossRefGoogle ScholarPubMed
12. Lu, J, McKinsey, TA, Zhang, C-L, Olso, EN. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Molecular Cell. 2000; 6, 233–244.CrossRefGoogle ScholarPubMed
13. Londhe, P, Davie, JK. Sequential association of myogenic regulatory factors and E proteins at muscle-specific genes. Skelet Muscle. 2011; 1, 14.CrossRefGoogle Scholar
14. Rajurkar, M, Huang, H, Cotton, JL, et al. Distinct cellular origin and genetic requirement of Hedgehog-Gli in postnatal rhabdomyosarcoma genesis. Oncogene. 2014; 33, 5370–5378.CrossRefGoogle ScholarPubMed
15. Saab, R, Spunt, SL, Skapek, SX. Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr Top Dev Biol. 2011; 94, 197–234.Google Scholar
16. Charytonowicz, E, Cordon-Cardo, C, Matushansky, I, Ziman, M. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell. Cancer Lett. 2009; 279, 126–136.Google Scholar
17. Hettmer, S, Wagers, AJ. Muscling in: uncovering the origins of rhabdomyosarcoma. Nat Med. 2010; 16, 171–173.Google Scholar
18. Rezvani, G, Lui, JC, Barnes, KM, Baron, J. A set of imprinted genes required for normal body growth also promotes growth of rhabdomyosarcoma cells. Pediatr Res. 2012; 71, 32–38.CrossRefGoogle ScholarPubMed
19. Wachtel, M, Dettling, M, Koscielniak, E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res. 2004; 64, 5539–5545.Google Scholar
20. Xia, SJ, Pressey, JG, Barr, FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther. 2002; 1, 97–104.Google Scholar
21. Langenau, DM, Keefe, MD, Storer, NY, et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 2007; 21, 1382–1395.CrossRefGoogle ScholarPubMed
22. Kalebic, T, Tsokos, M, Helman, LJ. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and downregulates p34cdc2 . Cancer Res. 1994; 54, 5531–5534.Google Scholar
23. Rubin, BP, Nishijo, K, Chen, HI, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 2011; 19, 177–191.CrossRefGoogle ScholarPubMed
24. Dagher, R, Helman, L. Rhabdomyosarcoma: an overview. Oncologist. 1999; 4, 34–44.Google Scholar
25. Ognjanovic, S, Carozza, SE, Chow, EJ, et al. Birth characteristics and risk of childhood rhabdomyosarcoma based on histological subtype. Br J Cancer. 2010; 102, 227–231.Google Scholar
26. Grufferman, S, Ruymann, F, Ognjanovic, S, Erhardt, EB, Maurer, HM. Prenatal X-ray exposure and rhabdomyosarcoma in children: a report from the children’s oncology group. Cancer Epidemiol Biomarkers Prev. 2009; 18, 1271–1276.Google Scholar
27. Ghali, MH, Yoo, KY, Flannery, JT, Dubrow, R. Association between childhood rhabdomyosarcoma and maternal history of stillbirths (Abstract). Int J Cancer. 1992; 50, 365–368.Google Scholar
28. Laurvick, CL, Milne, E, Blair, E, et al. Fetal growth and risk of childhood non-CNS tumors in Western Australia. Br J Cancer. 2008; 99, 179–181.Google Scholar
29. Sang, L, Coller, HA, Roberts, JM. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science. 2008; 321, 1095–1100.Google Scholar
30. Belyea, BC, Naini, S, Bentley, RC, Linardic, CM. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Clin Cancer Res. 2011; 17, 7324–7336.Google Scholar
31. Singh, S, Vinson, C, Gurley, CM, et al. Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice. Am J Pathol. 2010; 177, 2055–2066.Google Scholar
32. Hatley, ME, Tang, W, Garcia, MR, et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell. 2012; 22, 536–546.Google Scholar
33. Roma, J, Almazan-Moga, A, Sanchez de Toledo, J, Gallego, S. Notch, wnt, and hedgehog pathways in rhabdomyosarcoma: from single pathways to an integrated network. Sarcoma. 2012; 2012, 695603.Google Scholar
34. Rota, R, Ciarapica, R, Giordano, A, Miele, L, Locatelli, F. MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality. Mol Cancer. 2011; 10, 120.Google Scholar
35. McCarthy, JJ. MicroRNA-206: the skeletal muscle-specific myomiR. Biochim Biophys Acta. 2008; 1779, 682–691.CrossRefGoogle ScholarPubMed
36. Kim, HK, Lee, YS, Sivaprasad, U, Malhotra, A, Dutta, A. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol. 2006; 174, 677–687.Google Scholar
37. Anderson, C, Catoe, H, Werner, R. MIR-206 regulates connexin43 expression during skeletal muscle development. Nucleic Acids Res. 2006; 34, 5863–5871.Google Scholar
38. Khanna, N, Ge, Y, Chen, J. MicroRNA-146b promotes myogenic differentiation and modulates multiple gene targets in muscle cells. PLoS One. 2014; 9, e100657.Google Scholar
39. Cheung, TH, Quach, NL, Charville, GW, et al. Maintenance of muscle stem-cell quiescence by microRNA-489. Nature. 2012; 482, 524–528.Google Scholar
40. Rao, PK, Missiaglia, E, Shields, L, et al. Distinct roles of miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. Faseb J. 2010; 24, 3427–3437.Google Scholar
41. Taulli, R, Bersani, F, Foglizzo, V, et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest. 2009; 119, 2366–2378.Google Scholar
42. Wang, H, Garzon, R, Sun, H, et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008; 14, 369–381.Google Scholar
43. Walter, D, Satheesha, S, Albrecht, P, et al. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One. 2011; 6, e19506.Google Scholar
44. Sana, J, Zambo, I, Skoda, J, et al. CD133 expression and identification of CD133/Nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines. Anal Cell Pathol (Amst). 2011; 34, 303–318.Google Scholar
45. Goldblum, JR, Weiss, SW, Folpe, AL. Enzinger and Weiss’s Soft Tissue Tumors, 5th edn, 2008. Mosby Elsevier: China. pp. 565–579, (ISBN: 978-0-323-04628-2).Google Scholar
46. Sebire, NJ, Malone, M. Myogenin and Myo D1 expression in paediatric rhabdomyosarcomas. J Clin Pathol 2003; 56, 412–416.Google Scholar
47. Coindre, JM. Immunohistochemistry in the diagnosis of soft tissue tumours. Histopathology. 2003; 43, 1–16.Google Scholar